Hostname: page-component-848d4c4894-wzw2p Total loading time: 0 Render date: 2024-05-24T01:55:21.058Z Has data issue: false hasContentIssue false
  • English
  • Français

Screening for HIV Infection: Risks, Benefits, and the Burden of Proof

Published online by Cambridge University Press:  28 April 2021

Michael J. Barry ,
Paul D. Cleary  and
Harvey V. Fineberg
Get access Rights & Permissions [Opens in a new window]

Extract

In 1984, scientists isolated a new pathogen, now called human immunodeficiency virus (HIV), that is almost certainly the etiological agent for the acquired immunodeficiency syndrome (AIDS). It has been estimated that there are between 500,000 and 1,750,000 asymptomatic, chronically HIV-infected individuals in the United States. In a remarkably short time, investigators developed a number of blood tests that indicate whether an individual is likely to be infected with this virus. These assays are now being used to test patients with symptoms suggesting AIDS or related syndromes, to screen donated blood, to evaluate individuals concerned about their infection status, and to screen new military recruits, active-duty soldiers, and ROTC students. Almost weekly, new proposals are advanced for screening different subsets of the population.

Type
Article
Information
Law, Medicine and Healthcare , Volume 14 , Issue 5-6 , December 1986 , pp. 259 - 267
Copyright
Copyright © American Society of Law, Medicine and Ethics 1986

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Gallo, RC et al., Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS, Science 1984, 214: 500–503; Fauci, AS et al., The acquired immunodeficiency syndrome: An update, Annals of Internal Medicine 1985, 102: 800-813; Case, K, Nomenclature: Human immunodeficiency virus, Annals of Internal Medicine 1986, 105: 135.Google Scholar
Curran, JW, The epidemiology and prevention of the acquired immunodeficiency syndrome, Annals of Internal Medicine 1985, 103: 657–62; Sivak, SL, Wormser, GP, How common is HTLV-III infection in the United States? (letter), New England Journal of Medicine 1985, 313: 1352.CrossRefGoogle ScholarPubMed
Screening for AIDS, The Medical Letter 1985, 27: 29–30; Council on Scientific Affairs, American Medical Association, Status report on the acquired immunodeficiency syndrome, Journal of the American Medical Association 1985, 254: 1342-45.Google Scholar
Haynes, RB et al., Increased absenteeism from work after detection and labeling of hypertensive patients, New England Journal of Medicine 1978, 299: 741–44.Google ScholarPubMed
Bayer, R, Levine, C, Wolf, SM, HIV antibody screening: An ethical framework for evaluating proposed programs, Journal of the American Medical Association 1986, 256: 1768–74; Gostin, L, Acquired immune deficiency syndrome: A review of science, health policy, and law, AIDS: Science, Policy, and Law 1986, 4: 3-13.Google ScholarPubMed
Burger, H et al., Transmission of lymphadenopathyassociated virus/human T-lymphotropic virus type III in sexual partners: Seropositivity does not predict infectivity in all cases, American Journal of Medicine 1986, 81: 5–10.Google Scholar
Burger, H et al., Transient antibody to lymphadenopathy-associated virus/human T-lymphotropic virus type III and T-lymphocyte abnormalities in the wife of a man who developed the acquired immunodeficiency syndrome, Annals of Internal Medicine 1985, 103: 545–47.CrossRefGoogle ScholarPubMed
Francis, DP et al., The natural history of infection with the lymphadenopathy-associated virus human T-lymphotropic virus type III, Annals of Internal Medicine 1985, 103:719–22.Google ScholarPubMed
Carlson, JR et al., AIDS serology testing in low and high-risk groups, Journal of the American Medical Association 1985, 253: 3405–8.CrossRefGoogle ScholarPubMed
Food and Drug Administration, Summary of basis for approval: Virgo™ HTLV-III ELISA, FDA Freedom of Information Staff, HFV-35, Rockville, Md., Reference Nos. 84–574 and 85–024; Food and Drug Administration, Summary of basis for approval: Abbott HTLV-III EIA, FDA Freedom of Information Staff, HFV-35, Rockville, Md., Reference Nos. 84–580 and 85–019; Food and Drug Administration, Summary of basis for approval: HTLV-III Bio-EnzaBeadTM Test Kit, FDA Freedom of Information Staff, HFV-35, Rockville, Md., Reference Nos. 84–587 and 85–588.Google Scholar
Weinstein, MC, Fineberg, HV, Clinical decision analysis, Philadelphia: Saunders, 1980.Google Scholar
Safai, B et al., Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome, Lancet 1984, i: 1438–39; Essex, M et al., Antigens of human T-lymphotropic virus type III/lymphadenopathy-associated virus, Annals of Internal Medicine 1985, 103: 700-703; Gershoni, JM, Palade, GE, Protein blotting: Principles and applications, Analytical Biochemistry 1983, 131: 1-15.Google Scholar
Screening for AIDS, supra note 3; Mortimer, PP, Parry, JV, Mortimer, JY, Which anti-HTLV-III/LAV assays for screening and confirmatory testing?, Lancet 1985, ii: 873–77; Burke, DS, Redfield, RR, False-positive Western blot tests for antibodies to HTLV-III (letter), Journal of the American Medical Association 1986, 256: 347.Google Scholar
Sandstrom, EG et al., Detection of human anti-HTLV-III antibodies by indirect immunofluorescence using fixed cells, Transfusion 1985, 25: 308–12; Mortimer, PP et al., Prevalence of antibody to human T-lymphotropic virus type III by risk group and area, United Kingdom 1978–1984, British Medical Journal 1985, 290: 1176-78.CrossRefGoogle ScholarPubMed
Gallo, et al., supra note 1; Francis, et al., supra note 8.Google Scholar
Nicholson, JK et al., Exposure to human T-lymphotropic virus type III/lymphadenopathy-associated virus and immunologic abnormalities in asymptomatic homosexual men, Annals of Internal Medicine 1985, 103: 37–42.CrossRefGoogle ScholarPubMed
Pinching, AJ et al., Studies of cellular immunity in male homosexuals in London, Lancet 1983, ii: 126–30.Google Scholar
Redfield, RR, Wright, DC, Tramont, EC, The Walter Reed staging classification for HTLV-III/LAV infection, New England Journal of Medicine 1986, 314: 131–32; Centers for Disease Control, Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections, Annals of Internal Medicine 1986, 105: 234-37.CrossRefGoogle ScholarPubMed
Stevens, CE et al., Human T-cell lymphotropic virus type III infection in a cohort of homosexual men in New York City, Journal of the American Medical Association 1986, 255: 2167–72.Google Scholar
Id.; Francis, et al., supra note 8; Jaffe, HW et al., The acquired immunodeficiency syndrome in a cohort of homosexual men: A six year follow-up study, Annals of Internal Medicine 1985, 103: 210–14.Google Scholar
Morgan, J et al., Potential source of error in HTLV-III antibody testing (letter), Lancet 1986, i: 739–40; Barr, A et al., Anti-HTLV-III screening specificity and sensitivity (letter), Lancet 1986, i: 1032; Cayzer, I, Field, S, Elimination of source of error in HTLV-III antibody testing (letter), Lancet 1986, i: 1032–33.Google Scholar
Griner, PF et al., Selection and interpretation of diagnostic tests and procedures, Annals of Internal Medicine 1981, 94: 559–70.Google ScholarPubMed
Petricciani, JC, Licensed tests for antibody to human T-lymphotropic virus type III: Sensitivity and specificity, Annals of Internal Medicine 1985, 103: 726–29; FDA, supra note 10.CrossRefGoogle ScholarPubMed
Ransohoff, DF, Feinstein, AR, Problems of spectrum and bias in evaluating the efficacy of diagnostic tests, New England Journal of Medicine 1978, 299: 926–30.CrossRefGoogle ScholarPubMed
Burger, et al., supra note 7; Biggar, RJ et al., Variation in human T-lymphotropic virus III (HTLV-III) antibodies in homosexual men: Decline before onset of illness related to acquired immune deficiency syndrome (AIDS), British Medical Journal 1985, 291: 997–98.Google Scholar
Ho, DD et al., Primary human T-lymphotropic virus type III infection, Annals of Internal Medicine 1985, 103: 880–83; Yomtorian, R, HTLV-III antibody testing: The false negative rate (letter), New England Journal of Medicine 1986, 255: 609; Mayer, KH et al., Human T-lymphotropic virus type III in high-risk, antibody negative homosexual men, Annals of Internal Medicine 1986, 104: 194-96; Tucker, J et al., HTLV-III infection associated with glandular-fever-like illness in a haemophiliac Lancet 1985, i: 585.CrossRefGoogle ScholarPubMed
Salahuddin, SZ et al., HTLV-III in symptom-free seronegative persons, Lancet 1984, ii: 1418–22.CrossRefGoogle Scholar
Kuhnl, P, Seidl, S, Holzberger, G, HLA DR4 antibodies cause false positive HTLV-III antibody ELISA results (letter), Lancet 1985, i: 1222–23; Saag, MS, Britz, J, Asymptomatic blood donor with a false positive HTLV-III Western blot (letter), New England Journal of Medicine 1986, 314: 118.CrossRefGoogle Scholar
D'Aquila, R et al., Prevalence of HTLV-III infection among New Haven, Connecticut, parenteral drug abusers in 1982–1983 (letter), New England Journal of Medicine 1986, 314: 117–18.Google Scholar
Moore, JD, Cone, EJ, Alexander, SS, HTLV-III seropositivity in 1971–1972 parenteral drug abusers—A case of false positives or evidence of viral exposure? (letter), New England Journal of Medicine 1986, 314: 1387–88.Google Scholar
Mortimer, et al., supra note 13.Google Scholar
Sox, HC, Probability theory in the use of diagnostic tests, Annals of Internal Medicine 1986, 104: 60–66.CrossRefGoogle ScholarPubMed
Schorr, JB et al., Prevalence of HTLV-III antibody in American blood donors (letter), New England Journal of Medicine 1985, 313: 384–85; Kuritsky, JN et al., Results of nationwide screening of blood and plasma for antibodies to human T-cell lymphotropic virus, type III, Transfusion 1986, 26: 205-7.Google Scholar
Leads from the MMWR, Human T-lymphotropic virus type III/lymphadenopathy-associated virus antibody prevalence in U.S. military recruit applicants, Journal of the American Medical Association 1986, 256: 975–76.Google Scholar
Ward, JW et al., Laboratory and epidemiologic evaluation of an enzyme immunoassay for antibodies to HTLV-III, Journal of the American Medical Association 1986, 256: 357–61.CrossRefGoogle ScholarPubMed
Saag, and Britz, , supra note 28; HTLV-III and blood donors (editorial), Lancet 1985, i: 856.Google Scholar
Mayer, KH et al., Association of human T lymphotropic virus type III antibodies with sexual and other behaviors in a cohort of homosexual men from Boston with and without generalized lymphadenopathy, American Journal of Medicine 1986, 80: 357–63.CrossRefGoogle Scholar
D'Aquila, et al., supra note 29.Google Scholar
Moore, , Cone, and Alexander, , supra note 30; Katchaki, et al., Anti-HTLV-III screening and false positivity (letter), Lancet 1986, i: 448.Google Scholar
Peterman, TA et al., HTLV-III/LAV infection in hemodialysis patients, Journal of the American Medical Association 1986, 255: 2324–26.CrossRefGoogle ScholarPubMed
Mendenhall, CL et al., False positive tests for HTLV-III antibodies in alcoholic patients with hepatitis (letter), New England Journal of Medicine 1986, 314: 921–22.Google Scholar
Whittington, WL et al., The prevalence of HTLV-III/LAV antibodies in heterosexuals (letter), New England Journal of Medicine 1986, 255: 1702–3.Google Scholar
Ward, et al., supra note 35.Google Scholar